A detailed history of Geode Capital Management, LLC transactions in Glycomimetics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 521,223 shares of GLYC stock, worth $119,881. This represents 0.0% of its overall portfolio holdings.

Number of Shares
521,223
Previous 487,242 6.97%
Holding current value
$119,881
Previous $136,000 35.29%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.16 - $0.32 $5,436 - $10,873
33,981 Added 6.97%
521,223 $88,000
Q2 2024

Aug 09, 2024

SELL
$0.24 - $3.04 $4,297 - $54,431
-17,905 Reduced 3.54%
487,242 $136,000
Q1 2024

May 13, 2024

BUY
$2.55 - $3.49 $66,973 - $91,661
26,264 Added 5.48%
505,147 $1.52 Million
Q4 2023

Feb 13, 2024

BUY
$1.13 - $2.54 $21,512 - $48,356
19,038 Added 4.14%
478,883 $1.13 Million
Q3 2023

Nov 13, 2023

SELL
$1.29 - $1.73 $21,149 - $28,363
-16,395 Reduced 3.44%
459,845 $689,000
Q2 2023

Aug 11, 2023

BUY
$1.21 - $2.08 $85,795 - $147,482
70,905 Added 17.49%
476,240 $828,000
Q4 2022

Feb 13, 2023

BUY
$0.57 - $3.03 $26,755 - $142,228
46,940 Added 13.1%
405,335 $1.23 Million
Q2 2022

Aug 12, 2022

SELL
$0.54 - $1.15 $2,722 - $5,798
-5,042 Reduced 1.39%
358,395 $214,000
Q1 2022

May 13, 2022

SELL
$1.0 - $1.58 $1,669 - $2,637
-1,669 Reduced 0.46%
363,437 $414,000
Q4 2021

Feb 11, 2022

SELL
$1.44 - $2.14 $1,720 - $2,557
-1,195 Reduced 0.33%
365,106 $525,000
Q3 2021

Nov 12, 2021

BUY
$1.8 - $2.39 $24,409 - $32,410
13,561 Added 3.84%
366,301 $802,000
Q2 2021

Aug 13, 2021

SELL
$2.16 - $3.18 $793,668 - $1.17 Million
-367,439 Reduced 51.02%
352,740 $818,000
Q1 2021

May 12, 2021

BUY
$2.89 - $4.22 $136,552 - $199,395
47,250 Added 7.02%
720,179 $2.17 Million
Q4 2020

Feb 12, 2021

BUY
$2.69 - $4.24 $183,016 - $288,472
68,036 Added 11.25%
672,929 $2.53 Million
Q3 2020

Nov 13, 2020

BUY
$3.07 - $5.0 $201,066 - $327,470
65,494 Added 12.14%
604,893 $1.86 Million
Q2 2020

Aug 13, 2020

BUY
$2.06 - $3.76 $45,369 - $82,810
22,024 Added 4.26%
539,399 $2.03 Million
Q1 2020

May 14, 2020

BUY
$1.83 - $5.41 $49,420 - $146,102
27,006 Added 5.51%
517,375 $1.18 Million
Q4 2019

Feb 13, 2020

SELL
$4.03 - $6.5 $56,214 - $90,668
-13,949 Reduced 2.77%
490,369 $2.59 Million
Q3 2019

Nov 12, 2019

BUY
$2.8 - $12.85 $103,742 - $476,105
37,051 Added 7.93%
504,318 $2.17 Million
Q2 2019

Aug 14, 2019

BUY
$10.6 - $13.12 $235,224 - $291,145
22,191 Added 4.99%
467,267 $5.57 Million
Q1 2019

May 14, 2019

BUY
$9.96 - $13.44 $329,407 - $444,501
33,073 Added 8.03%
445,076 $5.55 Million
Q4 2018

Feb 13, 2019

BUY
$8.47 - $14.71 $486,110 - $844,236
57,392 Added 16.18%
412,003 $3.9 Million
Q3 2018

Nov 13, 2018

BUY
$13.7 - $17.12 $401,396 - $501,598
29,299 Added 9.01%
354,611 $5.11 Million
Q2 2018

Aug 14, 2018

BUY
$14.63 - $19.19 $1.81 Million - $2.38 Million
123,879 Added 61.5%
325,312 $5.25 Million
Q1 2018

May 15, 2018

BUY
$16.06 - $25.35 $714,364 - $1.13 Million
44,481 Added 28.34%
201,433 $3.27 Million
Q3 2017

Nov 14, 2017

BUY
$10.14 - $14.85 $113,061 - $165,577
11,150 Added 7.65%
156,952 $2.2 Million
Q2 2017

Aug 14, 2017

BUY
N/A
145,802
145,802 $1.63 Million

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $12.1M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.